U.S. FDA approval of BioLineRx’s APHEXDA™ (Motixafortide) in combination with Filgrastim (G-CSF) – a ray of hope for patients with Multiple Myeloma
BioLineRx Ltd., a commercial stage biopharmaceutical company, is constantly driving innovation by discovering, in-licensing, and developing promising drug candidates for patients with multiple myeloma, sickle cell disease, pancreatic cancer, and other solid tumors.
With its recent approval for APHEXDA™ (Motixafortide) in combination with Filgrastim (G-CSF) for adequate mobilization of stem cells in autologous stem cell transplantation (ASCT) during multiple myeloma treatment, it has proved that the company is focused on aggressively finding, patenting, and developing novel compounds for various types of cancers. It has also patented the combinations of Motixafortide with other drugs such as PD-1 inhibitors (Cemiplimab, Pembrolizumab) and CD20 inhibitor (Rituximab) to treat multiple myeloma and second-line metastatic pancreatic cancer.
BL-8040’s (Motixafortide) intellectual property portfolio includes, inter alia, granted patents like:
Patent Number | Title | Applicant |
US8455450B2 | Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof | BIOKINE THERAPEUTICS LTD |
US8765683B2 | T-140 peptide analogs having CXCR4 super-agonist activity for cancer therapy | BIOKINE THERAPEUTICS LTD |
US8663651B2 | T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation | BIOKINE THERAPEUTICS LTD |
US11648293B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD; BIOLINERX LTD |
US7423007B2 | CXCR4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD |
US8017585B2 | CXCR4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD |
US8410059B2 | CXCR4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD |
US10993985B2 | Methods of treating acute myeloid leukemia | BIOLINERX LTD; BIOKINE THERAPEUTICS LTD; BIOLMERX LTD |
On August 27, 2023, BioLineRx Ltd. also entered into a license agreement with Hong Seng Technology Limited and Guangzhou Gloria Biosciences Co., Ltd., pursuant to which the Company granted HST an exclusive, royalty-bearing, sublicensable license with respect to the intellectual property rights and know-how associated with Motixafortide (BL-8040) in order to develop and commercialize Motixafortide in Asia (other than Israel and certain other countries) and to engage and authorize Gloria to perform services under the License Agreement in Asia. This can give a significant boost to cancer patients in Asia1.
References: